2024
Psychotic Disorders and Schizophrenia
Surti T. Psychotic Disorders and Schizophrenia. 2024 DOI: 10.1016/b978-0-323-95702-1.00074-9.Peer-Reviewed Original ResearchPsychotic disordersSymptoms of schizophrenia-spectrum disordersDifferential diagnosis of schizophreniaSchizophrenia spectrum disordersDiagnosis of schizophreniaDecreased emotional expressionNon-psychiatric conditionsAssociated with increased disabilityPsychotic symptomsDisorganized speechDisorganized behaviorCognitive symptomsPsychotic diseasesEmotional expressionSchizophreniaLack of motivationDisordersSymptomsClinical presentationDifferential diagnosisClinical managementDelusionsHallucinationsRisk factorsIncreased mortality
2023
Snoozing on Pot: Cannabis and Sleep
Skosnik P, Surti T. Snoozing on Pot: Cannabis and Sleep. 2023, 333-345. DOI: 10.1017/9781108943246.032.Peer-Reviewed Original ResearchMental illnessMental health teamsHealth policy implicationsHigh-potency cannabisStages of neurodevelopmentPotential adverse effectsHealth teamsImpact of exposureCannabis dependenceAdverse effectsCannabisSynthetic cannabinoidsIllnessPsychosisCannabinoidsNew research findingsAssociationComplex associationNeurodevelopmentPutative modelSleepSchizophreniaRandomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia
Surti T, Ranganathan M, Johannesen J, Gueorguieva R, Deaso E, Kenney J, Krystal J, D'Souza D. Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia. Schizophrenia Research 2023, 256: 36-43. PMID: 37141764, PMCID: PMC10257994, DOI: 10.1016/j.schres.2023.04.010.Peer-Reviewed Original ResearchConceptsGlycine transporter 1Cytochrome P450 2D6 extensive metabolizersGlyT1 inhibitorsWeeks of washoutWeeks of CTMedication adherenceReceptor hypofunctionImpaired neuroplasticityPharmacodynamic variabilityNMDAR functionExtensive metabolizersTreatment periodPsychotic symptomsStable outpatientsCognitive impairmentGlyT1 occupancyTransporter 1CTNeuroplasticityCognitive training strategiesSchizophreniaComputerized CTCognitive performanceAugmentation studiesGreater improvement
2022
Eulerian Phase-based Motion Magnification for High-Fidelity Vital Sign Estimation with Radar in Clinical Settings
Oshim F, Surti T, Goldfine C, Carreiro S, Ganesan D, Jayasuriya S, Rahman T. Eulerian Phase-based Motion Magnification for High-Fidelity Vital Sign Estimation with Radar in Clinical Settings. 2022, 00: 1-4. DOI: 10.1109/sensors52175.2022.9967051.Peer-Reviewed Original ResearchEulerian phaseFundamental frequency estimationMachine learning modelsFrequency estimationVital sign estimationMotion magnificationFilter outputSubtle motionsVital sign monitoringLearning modelHuman postureWavelength levelGabor filter outputsNoisy environmentsSign estimationDecomposition methodSmall objectsAccurate detectionMotionRadarMotion signalsEstimationGreater accuracyPhaseFFTIllness Phase as a Key Assessment and Intervention Window for Psychosis
Kohler C, Wolf D, Abi-Dargham A, Anticevic A, Cho Y, Fonteneau C, Gil R, Girgis R, Gray D, Grinband J, Javitch J, Kantrowitz J, Krystal J, Lieberman J, Murray J, Ranganathan M, Santamauro N, Van Snellenberg J, Tamayo Z, Group T, D'Souza D, Srihari V, Gueorguieva R, Patel P, Forselius-Bielen K, Lu J, Butler A, Fram G, Afriyie-Agyemang Y, Selloni A, Cadavid L, Gomez-Luna S, Gupta A, Radhakrishnan R, Rashid A, Aker R, Abrahim P, Nia A, Surti T, Kegeles L, Carlson M, Goldberg T, Gangwisch J, Benedict E, Govil P, Brazis S, Mayer M, de la Garrigue N, Fallon N, Baumvoll T, Abeykoon S, Perlman G, Bobchin K, Elliott M, Schmidt L, Rush S, Port A, Heffernan Z, Laney N, Kantor J, Hohing T, Gur R, Gur R, Calkins M. Illness Phase as a Key Assessment and Intervention Window for Psychosis. Biological Psychiatry Global Open Science 2022, 3: 340-350. PMID: 37519466, PMCID: PMC10382701, DOI: 10.1016/j.bpsgos.2022.05.009.Peer-Reviewed Original ResearchIllness phasePotential critical windowsPhase-specific biomarkersDopaminergic abnormalitiesFunctional outcomeSpecialty careSymptom assessmentIllness stageChronic illnessClinical assessmentIllness trajectoryNeurophysiological biomarkersFunctional abnormalitiesClinical careEarly psychosisMemory dysfunctionPsychotic disordersTreatment targetsAllostatic adaptationIntervention windowClinical programsBrain developmentCritical windowDysfunctionIllness
2021
Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia
Abi-Dargham A, Javitch JA, Slifstein M, Anticevic A, Calkins ME, Cho YT, Fonteneau C, Gil R, Girgis R, Gur RE, Gur RC, Grinband J, Kantrowitz J, Kohler C, Krystal J, Murray J, Ranganathan M, Santamauro N, Van Snellenberg J, Tamayo Z, Wolf D, D’Souza D, Srihari V, Gueorguieva R, Patel P, Forselius-Bielen K, Lu J, Butler A, Fram G, Afriyie-Agyemang Y, Selloni A, Cadavid L, Gomez-Luna S, Gupta A, Radhakrishnan R, Rashid A, Aker R, Abrahim P, Nia A, Surti T, Kegeles L, Carlson M, Goldberg T, Gangwisch J, Benedict E, Govil P, Brazis S, Mayer M, de la Garrigue N, Fallon N, Baumvoll T, Abeykoon S, Perlman G, Bobchin K, Elliott M, Schmidt L, Rush S, Port A, Heffernan Z, Laney N, Kantor J, Hohing T, Gray D, Lieberman J. Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia. Schizophrenia Bulletin 2021, 48: 199-210. PMID: 34423843, PMCID: PMC8781338, DOI: 10.1093/schbul/sbab095.Peer-Reviewed Original ResearchConceptsCortical dopamine neurotransmissionPositive allosteric modulationImportant therapeutic targetPF-06412562Dopaminergic receptorsD1R stimulationDA levelsTolerable dosesLevel of stimulationDopamine neurotransmissionReceptor stimulationTherapeutic targetPartial agonistCognitive deficitsBiased agonismFull agonismTarget engagementAllosteric modulationNew drugsStimulationPoor bioavailabilitySchizophreniaOptimal stimulationDrugsExpression levels
2018
168. The Effect of Fatty Acid Amide Hydrolase Inhibition on Sleep Architecture in Cannabis Withdrawal
Skosnik P, Cortes-Briones J, Creatura G, Morgan P, Ranganathan M, Deaso E, Surti T, D'Souza D. 168. The Effect of Fatty Acid Amide Hydrolase Inhibition on Sleep Architecture in Cannabis Withdrawal. Biological Psychiatry 2018, 83: s68. DOI: 10.1016/j.biopsych.2018.02.186.Peer-Reviewed Original Research
2015
Rapid Changes in Cannabinoid 1 Receptor Availability in Cannabis-Dependent Male Subjects After Abstinence From Cannabis.
D'Souza D, Cortes-Briones J, Ranganathan M, Thurnauer H, Creatura G, Surti T, Planeta B, Neumeister A, Pittman B, Normandin M, Kapinos M, Ropchan J, Huang Y, Carson R, Skosnik P. Rapid Changes in Cannabinoid 1 Receptor Availability in Cannabis-Dependent Male Subjects After Abstinence From Cannabis. Biological Psychiatry Cognitive Neuroscience And Neuroimaging 2015, 1: 60-67. PMID: 29560896, DOI: 10.1016/j.bpsc.2015.09.008.Peer-Reviewed Original Research
2001
Approaches to solving the rigid receptor problem by identifying a minimal set of flexible residues during ligand docking11PDB coordinates have been deposited with the RSCB with accession ID: 1F28.
Anderson A, O’Neil R, Surti T, Stroud R. Approaches to solving the rigid receptor problem by identifying a minimal set of flexible residues during ligand docking11PDB coordinates have been deposited with the RSCB with accession ID: 1F28. Cell Chemical Biology 2001, 8: 445-457. PMID: 11358692, DOI: 10.1016/s1074-5521(01)00023-0.Peer-Reviewed Original ResearchConceptsStructure-based drug designProtein targetsDrug designFlexible residuesHigh-resolution crystal structuresProtein/ligand complexesNew conformationDrug leadsEnzyme conformational changeThymidylate synthaseCrystal structureStructure of enzymesPossible conformationsAccession IDConformational adaptationConformational changesLigand complexesExperimental kinetic dataDrug moleculesTarget siteResiduesActive siteAntifolate inhibitorsNovel ligandsKinetic data
1998
Structural models of the bovine papillomavirus E5 protein
Surti T, Klein O, Aschheim K, DiMaio D, Smith S. Structural models of the bovine papillomavirus E5 protein. Proteins Structure Function And Bioinformatics 1998, 33: 601-612. PMID: 9849943, DOI: 10.1002/(sici)1097-0134(19981201)33:4<601::aid-prot12>3.0.co;2-i.Peer-Reviewed Original ResearchConceptsBovine papillomavirus E5 proteinE5 dimerE5 proteinType II integral membrane proteinIntegral membrane proteinsPrevious mutagenesis studiesLigand-independent activationDisulfide-linked homodimerPDGF beta receptorMembrane proteinsTransmembrane orientationMutagenesis studiesMembrane bilayerCell transformationGenetic resultsProteinGln17Receptor moleculesMolecular scaffoldsComplex formationAsp33Computational searchDimerizationDimer structureDimersRole of glutamine 17 of the bovine papillomavirus E5 protein in platelet-derived growth factor beta receptor activation and cell transformation.
Klein O, Polack G, Surti T, Kegler-Ebo D, Smith S, DiMaio D. Role of glutamine 17 of the bovine papillomavirus E5 protein in platelet-derived growth factor beta receptor activation and cell transformation. Journal Of Virology 1998, 72: 8921-32. PMID: 9765437, PMCID: PMC110309, DOI: 10.1128/jvi.72.11.8921-8932.1998.Peer-Reviewed Original ResearchConceptsBovine papillomavirus E5 proteinPDGF beta receptorE5 proteinTransform cellsCellular platelet-derived growth factor (PDGF) beta receptorAmino acidsBa/F3 hematopoietic cellsPosition 17Cell transformationPlatelet-derived growth factor beta receptorHomodimeric transmembrane proteinReceptor tyrosine phosphorylationGrowth factor beta receptorReceptor tyrosine kinasesPDGF receptor tyrosine kinaseReceptor activationPossible amino acidsBeta receptorsStable complexesComplex formationMutant proteinsTransmembrane domainTransmembrane proteinGrowth factor-beta (TGF-beta) receptor activationTyrosine phosphorylation